AML, ALL, CML, and CLL are the four major types of leukemia, and while they all involve cancerous white blood cells, they behave very differently — different age groups, different prognosis, different treatments. AML and ALL are acute leukemias that progress rapidly over days to weeks. CML and CLL are chronic leukemias that develop slowly, sometimes over years. The second distinction is cell lineage: AML and CML arise from myeloid cells, while ALL and CLL arise from lymphoid cells.
If you’re trying to make sense of these four abbreviations — whether for a new diagnosis, a family member’s care, or a medical exam — this guide breaks down the key insights into leukemia type by type, with real numbers and practical comparisons.
AML, ALL, CML, and CLL at a Glance
| Feature | AML | ALL | CML | CLL |
|---|---|---|---|---|
| Full Name | Acute Myeloid Leukemia | Acute Lymphoblastic Leukemia | Chronic Myeloid Leukemia | Chronic Lymphocytic Leukemia |
| Speed of Onset | Rapid (days–weeks) | Rapid (days–weeks) | Slow (months–years) | Slow (months–years) |
| Cell Type Affected | Myeloid (blasts) | Lymphoid (blasts) | Myeloid (mature granulocytes) | Lymphoid (mature B-cells) |
| Median Age at Diagnosis | 68 years | 15 years (peak 2–5 yrs) | 64 years | 72 years |
| New U.S. Cases/Year (est.) | ~20,800 | ~6,500 | ~9,000 | ~20,700 |
| 5-Year Survival Rate | ~31% | ~70% (children >90%) | ~70% | ~88% |
| Key Genetic Marker | FLT3, NPM1, t(8;21) | Philadelphia chromosome (Ph+), ETV6-RUNX1 | Philadelphia chromosome (BCR-ABL1) | del(13q), del(17p), TP53 |
These numbers come from SEER (Surveillance, Epidemiology, and End Results) data and the American Cancer Society’s 2024 estimates. Survival rates vary enormously based on age, genetics, and how early treatment begins.
How Symptoms Differ Across the Four Types
All four leukemias can cause fatigue, frequent infections, unexplained bruising, and fever — these are the hallmarks of a bone marrow that isn’t producing normal blood cells. But the clinical presentation often diverges from there.
AML Symptoms
AML hits fast. Patients often go from feeling fine to critically ill within weeks. Common findings include severe fatigue, pallor, bleeding gums, petechiae (tiny red spots on the skin), and shortness of breath. Some patients develop leukemia cutis — skin nodules caused by leukemia cells infiltrating the skin. A CBC often shows a WBC count that’s either extremely high (>100,000/µL in some cases) or paradoxically low, with blast cells visible on the peripheral smear.
ALL Symptoms
In children, ALL frequently presents with bone pain — kids may limp or refuse to walk. Lymph node swelling, hepatosplenomegaly (enlarged liver and spleen), and joint pain are common. Adults with ALL tend to present similarly to AML but may have more prominent lymphadenopathy. CNS involvement (headaches, vomiting, cranial nerve palsies) occurs in roughly 5–8% of cases at diagnosis.
CML Symptoms
Many CML patients are diagnosed incidentally when a routine blood test shows an elevated WBC count — often 50,000–200,000/µL with a characteristic “left shift” showing cells at every stage of myeloid maturation. When symptoms do appear, they typically include night sweats, early satiety, and a dragging sensation in the left upper abdomen from an enlarged spleen. About 40% of CML patients are asymptomatic at diagnosis.
CLL Symptoms
CLL is the slowest of the four. Up to 70% of patients have no symptoms at diagnosis — it’s picked up on routine bloodwork showing a persistent lymphocyte count above 5,000/µL. Over time, patients may develop painless swollen lymph nodes, recurrent infections (due to immune dysfunction), and autoimmune cytopenias like hemolytic anemia or immune thrombocytopenia.
Causes and Risk Factors
No one “causes” their own leukemia, but certain factors increase risk:
- AML: Prior chemotherapy (especially alkylating agents and topoisomerase II inhibitors), benzene exposure, smoking, myelodysplastic syndrome (MDS), and genetic conditions like Down syndrome and Fanconi anemia.
- ALL: Prior radiation or chemotherapy exposure, Down syndrome, and certain inherited syndromes. The cause of childhood ALL remains largely unknown — most cases occur without any identifiable risk factor.
- CML: The Philadelphia chromosome — a translocation between chromosomes 9 and 22, creating the BCR-ABL1 fusion gene — is found in over 95% of CML cases. This isn’t inherited; it’s an acquired mutation. Radiation exposure is the only consistently identified external risk factor.
- CLL: Family history matters here more than in other leukemias. First-degree relatives of CLL patients have a 6–9x increased risk. Exposure to Agent Orange (Vietnam-era herbicide) is a recognized risk factor by the VA.
How Each Type Is Diagnosed
Diagnosis always starts with a complete blood count (CBC) with differential and a peripheral blood smear. But the confirmatory workup differs:
- AML: Bone marrow biopsy showing ≥20% myeloid blasts. Flow cytometry identifies myeloid markers (CD33, CD13, MPO). Cytogenetics and molecular testing (FLT3, NPM1, CEBPA) guide prognosis and treatment.
- ALL: Bone marrow biopsy with ≥20% lymphoblasts. Flow cytometry distinguishes B-cell from T-cell ALL. Philadelphia chromosome testing is critical — Ph+ ALL requires targeted therapy.
- CML: Peripheral blood alone often suffices. A markedly elevated WBC with full myeloid maturation is classic. Confirmation requires detection of BCR-ABL1 by FISH or PCR. Bone marrow biopsy is performed for staging.
- CLL: Diagnosed by peripheral blood flow cytometry showing a clonal B-cell population ≥5,000/µL with a characteristic immunophenotype (CD5+, CD19+, CD23+). Bone marrow biopsy is often unnecessary for diagnosis but may be done before treatment.
Treatment Overview
Treatment strategies vary dramatically across the four types:
AML is treated with intensive induction chemotherapy (“7+3” — 7 days of cytarabine plus 3 days of an anthracycline). Patients who achieve remission may proceed to consolidation chemo or allogeneic stem cell transplant. Targeted agents like midostaurin (for FLT3+) and venetoclax have expanded options, especially for older patients who can’t tolerate intensive chemo.
ALL in children follows multi-agent chemotherapy protocols lasting 2–3 years with induction, consolidation, and maintenance phases. Cure rates exceed 90% in standard-risk pediatric ALL. Adults fare worse (~40–50% long-term survival), though newer therapies like blinatumomab (a bispecific T-cell engager) and CAR-T cell therapy (tisagenlecleucel) have changed outcomes for relapsed disease.
CML was revolutionized by imatinib (Gleevec), the first tyrosine kinase inhibitor (TKI), approved in 2001. Today, most patients take a daily TKI pill (imatinib, dasatinib, nilotinib, or bosutinib) and achieve deep molecular remission. Some patients who sustain deep response for ≥2 years can attempt treatment-free remission — essentially stopping medication under close monitoring.
CLL often follows a “watch and wait” approach for early-stage, asymptomatic patients. When treatment is needed, first-line options now include BTK inhibitors (ibrutinib, acalabrutinib, zanubrutinib) and venetoclax + obinutuzumab. Traditional chemoimmunotherapy (FCR) is still used in select younger patients with favorable genetics. The prognosis is generally good, though CLL with del(17p) or TP53 mutations carries a more guarded outlook.
When to See a Doctor
Get medical attention promptly if you experience:
- Persistent, unexplained fatigue that doesn’t improve with rest
- Recurrent fevers or infections over several weeks
- Unusual bruising, bleeding gums, or petechiae without trauma
- Painless, progressively enlarging lymph nodes
- Unexplained weight loss (>5% of body weight over 6 months)
- A blood test showing abnormal WBC count — especially above 15,000/µL or below 4,000/µL without an obvious cause like infection
Ask your doctor for a CBC with differential as a starting point. If results are abnormal, a referral to a hematologist should follow quickly — for acute leukemias, this is genuinely urgent.
Frequently Asked Questions
Which type of leukemia has the worst prognosis?
AML in older adults carries the lowest survival rates, with a 5-year overall survival around 31%. Patients over 65 with adverse cytogenetics may have a median survival under 12 months. However, prognosis is highly individual — genetic subtype matters as much as the leukemia category itself.
Can leukemia be cured, or is it always chronic?
Childhood ALL is cured in over 90% of cases. AML can be cured with intensive chemo and transplant, particularly in younger patients. CML isn’t typically “cured” but is controlled long-term with TKIs — many patients have a normal life expectancy. CLL is generally not curable but is highly manageable, with many patients living 10–20+ years after diagnosis.
What’s the difference between acute and chronic leukemia?
Acute leukemias (AML, ALL) involve immature blast cells that multiply rapidly and crowd out normal blood cells within weeks. Without treatment, acute leukemia is fatal within months. Chronic leukemias (CML, CLL) involve more mature cells that accumulate slowly — patients may live years without symptoms or treatment.
Is leukemia hereditary?
Most leukemias are not directly inherited. CLL has the strongest familial component — relatives of CLL patients have roughly a 6–9 fold increased risk. Certain genetic syndromes (Down syndrome, Li-Fraumeni syndrome, Fanconi anemia) predispose to leukemia, but these account for a small minority of cases.
What blood test results suggest leukemia?
A CBC may show a very high or very low WBC count, low hemoglobin (anemia), and/or low platelets (thrombocytopenia). In acute leukemias, blast cells may appear on the peripheral smear. In CLL, a persistent absolute lymphocyte count above 5,000/µL is the hallmark. Any unexplained CBC abnormality warrants further evaluation.
